EE05533B1 - Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine - Google Patents

Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine

Info

Publication number
EE05533B1
EE05533B1 EEP200200401A EEP200200401A EE05533B1 EE 05533 B1 EE05533 B1 EE 05533B1 EE P200200401 A EEP200200401 A EE P200200401A EE P200200401 A EEP200200401 A EE P200200401A EE 05533 B1 EE05533 B1 EE 05533B1
Authority
EE
Estonia
Prior art keywords
drospirenone
strogen
pharmaceutical composition
preparation containing
composition
Prior art date
Application number
EEP200200401A
Other languages
English (en)
Estonian (et)
Inventor
Heil Wolfgang
Hilmann J�rgen
Lipp Ralph
Sch�rmann Rolf
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071749&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05533(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200200401A publication Critical patent/EE200200401A/xx
Publication of EE05533B1 publication Critical patent/EE05533B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
EEP200200401A 2000-01-18 2001-01-18 Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine EE05533B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48402600A 2000-01-18 2000-01-18
EP00200183 2000-01-18
PCT/IB2001/000041 WO2001052857A1 (fr) 2000-01-18 2001-01-18 Drospirenone pour therapie de remplacement d'hormone

Publications (2)

Publication Number Publication Date
EE200200401A EE200200401A (et) 2003-10-15
EE05533B1 true EE05533B1 (et) 2012-04-16

Family

ID=26071749

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200401A EE05533B1 (et) 2000-01-18 2001-01-18 Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine

Country Status (30)

Country Link
EP (2) EP1257280B1 (fr)
JP (2) JP5128743B2 (fr)
KR (2) KR100913910B1 (fr)
CN (2) CN1395488A (fr)
AT (2) ATE305789T1 (fr)
AU (3) AU2541301A (fr)
BG (1) BG65849B1 (fr)
BR (1) BR0107683A (fr)
CA (1) CA2394165C (fr)
CY (1) CY1109567T1 (fr)
CZ (1) CZ20022411A3 (fr)
DE (2) DE60139907D1 (fr)
DK (2) DK1257280T3 (fr)
EE (1) EE05533B1 (fr)
ES (2) ES2332226T3 (fr)
HK (1) HK1047248B (fr)
HU (1) HUP0204291A3 (fr)
IL (3) IL150775A0 (fr)
ME (1) ME00292B (fr)
MX (1) MXPA02006613A (fr)
NO (1) NO335570B1 (fr)
NZ (1) NZ520630A (fr)
PL (1) PL201878B1 (fr)
PT (1) PT1611892E (fr)
RS (1) RS52149B (fr)
RU (2) RU2275198C2 (fr)
SI (2) SI1257280T1 (fr)
SK (2) SK287719B6 (fr)
WO (1) WO2001052857A1 (fr)
ZA (2) ZA200206551B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ
EP1216713A1 (fr) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Compositions de complexes de estrogen-cyclodextrine
JP2004521951A (ja) 2001-07-13 2004-07-22 シエーリング アクチエンゲゼルシャフト Ｈｒｔのためのドロスピレノン及びエストロゲンスルファメートの組み合わせ
DK1482948T3 (da) * 2002-03-11 2006-11-27 Janssen Pharmaceutica Nv Kontinuerlig sulfataseinhiberende progestogen-hormonsubstitutionsbehandling
KR20040104632A (ko) * 2002-04-26 2004-12-10 쉐링 악티엔게젤샤프트 호르몬 대체 요법을 받는 여성에서 고혈압의 치료
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
WO2004041288A1 (fr) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Therapie de remplacement d'hormone a l'aide de drospirenone
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
ATE429900T1 (de) * 2004-03-10 2009-05-15 Bayer Schering Pharma Ag Zusammensetzungen aus drospirenon in molekularer dispersion
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US8022053B2 (en) 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
CA2614187A1 (fr) * 2005-07-15 2007-01-25 Bayer Schering Pharma Aktiengesellschaft Dispositifs d'administration d'un medicament transdermique contenant le drospirenone
DE102005056527A1 (de) * 2005-11-25 2007-07-12 Grünenthal GmbH Verwendung einer Kombination aus Ethinylestradiol und Chlormadinonacetat zur Herstellung eines Arzneimittels
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en) 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
CN102985070A (zh) * 2010-04-15 2013-03-20 拜耳知识产权有限责任公司 用于hrt的极低剂量的固体口服剂型
EP2558076B1 (fr) * 2010-04-15 2014-12-24 Bayer Intellectual Property GmbH Forme galenique orale solide a faible dose pour le ths
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
BR112014010590A2 (pt) 2011-11-04 2017-05-02 Bayer Ip Gmbh 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
TW201350122A (zh) * 2012-04-23 2013-12-16 Bayer Pharma AG １８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內用途，包含１８－甲基－１５β，１６β－亞甲基－１９－降－２０－螺氧－４－烯－３－酮的子宮內系統，及其於避孕及婦科治療之用途
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
EP4098264A1 (fr) * 2017-06-01 2022-12-07 Nexyon Biotech Co., Ltd. Composition pharmaceutique pour la prévention ou le traitement d'une maladie osseuse
TWI801561B (zh) * 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CN111989105B (zh) * 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
CN115813937B (zh) * 2022-12-01 2025-04-11 南通联亚药业股份有限公司 一种稳定的包含屈螺酮和雌二醇的药物组合物及其制备方法
CN118356456A (zh) * 2024-04-17 2024-07-19 且安生物科技有限责任公司 一种抗炎护巢草本提取制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
JPH07114946B2 (ja) * 1988-10-24 1995-12-13 株式会社奈良機械製作所 難溶性物質の処理方法
JP2859919B2 (ja) * 1990-03-15 1999-02-24 旭化成工業株式会社 難溶性薬物の溶出性改善方法
NL9301562A (nl) * 1993-09-09 1995-04-03 Saturnus Ag Preparaat voor substitutietherapie.
JPH07112928A (ja) * 1993-10-15 1995-05-02 Freunt Ind Co Ltd 難溶性薬物の溶解性改善方法およびそれにより得られた粒状薬剤
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
JP4022269B2 (ja) * 1995-05-26 2007-12-12 協和醗酵工業株式会社 医薬組成物
US5897539A (en) * 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
DE69729956T2 (de) * 1996-07-26 2004-12-16 Wyeth Orale einstufige empfängnisverhütungsmethode und kombinationspräparat das gestagen und estrogen enthält
WO1998004266A1 (fr) * 1996-07-26 1998-02-05 American Home Products Corporation Contraceptif oral
DE19633685C1 (de) * 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
JPH10182701A (ja) * 1996-12-26 1998-07-07 Sanei Toka Kk 溶出性向上粉末及びその製造方法
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
JP4354667B2 (ja) * 1999-08-31 2009-10-28 バイエル・シエーリング・ファーマ・アクチエンゲゼルシャフト 避妊薬としての使用へのエチニルエストラジオールとドロスピレノンの医薬用組合せ

Also Published As

Publication number Publication date
RU2002122113A (ru) 2004-03-10
KR100913910B1 (ko) 2009-08-26
CZ20022411A3 (cs) 2003-02-12
EP1257280A1 (fr) 2002-11-20
PT1611892E (pt) 2009-11-20
KR100747965B1 (ko) 2007-08-08
SK287719B6 (en) 2011-07-06
IL150775A0 (en) 2003-02-12
JP5563227B2 (ja) 2014-07-30
NO20022966D0 (no) 2002-06-20
IL150775A (en) 2008-08-07
WO2001052857A1 (fr) 2001-07-26
ATE442147T1 (de) 2009-09-15
PL356987A1 (en) 2004-07-12
KR20020088066A (ko) 2002-11-25
EE200200401A (et) 2003-10-15
DK1611892T3 (da) 2009-11-02
ES2332226T3 (es) 2010-01-29
HUP0204291A3 (en) 2003-05-28
AU2001225413B2 (en) 2005-06-23
CN101934078A (zh) 2011-01-05
HK1047248A1 (en) 2003-02-14
SI1257280T1 (sl) 2006-02-28
CN1395488A (zh) 2003-02-05
DK1257280T3 (da) 2005-12-12
ME00292B (fr) 2011-05-10
DE60113809T2 (de) 2006-06-22
JP2003520239A (ja) 2003-07-02
SI1611892T1 (sl) 2010-01-29
BR0107683A (pt) 2002-11-12
HK1047248B (en) 2005-12-30
JP2009120615A (ja) 2009-06-04
RU2005140938A (ru) 2007-07-10
RS52149B (sr) 2012-08-31
ZA200601285B (en) 2008-01-08
CA2394165A1 (fr) 2001-07-26
AU2005209600B2 (en) 2008-08-07
SK288129B6 (sk) 2013-10-02
BG65849B1 (bg) 2010-03-31
AU2005209600A1 (en) 2005-09-29
DE60113809D1 (de) 2006-02-16
JP5128743B2 (ja) 2013-01-23
IL191131A (en) 2010-12-30
NO335570B1 (no) 2014-12-29
EP1611892A3 (fr) 2006-02-01
HUP0204291A2 (hu) 2003-04-28
AU2541301A (en) 2001-07-31
EP1257280B1 (fr) 2005-10-05
PL201878B1 (pl) 2009-05-29
RU2402331C2 (ru) 2010-10-27
EP1611892B1 (fr) 2009-09-09
DE60139907D1 (de) 2009-10-22
HK1082433A1 (en) 2006-06-09
NZ520630A (en) 2004-09-24
SK10322002A3 (sk) 2003-03-04
YU54602A (sh) 2006-01-16
ZA200206551B (en) 2006-04-29
MXPA02006613A (es) 2003-10-15
KR20070051956A (ko) 2007-05-18
RU2275198C2 (ru) 2006-04-27
ES2247054T3 (es) 2006-03-01
IL191131A0 (en) 2008-11-03
ATE305789T1 (de) 2005-10-15
MEP38008A (en) 2011-02-10
CY1109567T1 (el) 2014-08-13
NO20022966L (no) 2002-09-18
BG106915A (bg) 2003-04-30
EP1611892A2 (fr) 2006-01-04
CA2394165C (fr) 2010-04-13

Similar Documents

Publication Publication Date Title
EE05533B1 (et) Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja ”strogeeni ning nende kasutamine
CA2294337A1 (fr) Preparation de compositions pharmaceutiques
WO2001085257A3 (fr) Compositions d'antagoniste opioide et formes de dosage
CA2366702A1 (fr) Compositions et procedes d'administration amelioree d'agents therapeutiques hydrophobes ionisables
WO2001066085A3 (fr) Compositions pharmaceutiques destinees a une application buccale et pulmonaire
CA2339991A1 (fr) Microemulsions comme formes pharmaceutiques solides destinees a une administration orale
WO2000007979A3 (fr) Composes et compositions pour l'administration de principes actifs
CA2318128A1 (fr) Compositions liquides orales
MXPA02011436A (es) Composiciones farmaceuticas micelares para aplicacion bucal y pulmonar.
EP1598069A3 (fr) Combinaison pharmaceutique d'éthinylestradiol et de drospirénone comme contraceptif
WO2003013433A3 (fr) Formulations d'antagoniste sequestre
HK1047036A1 (zh) 用於治疗偏头痛的选择性iglur5，受体拮抗剂
HUP0203721A2 (hu) Új hormonkészítmény és alkalmazása
EP0867181A1 (fr) Composition nasale de mélatonine
DE69501183D1 (de) Feste orale pharmazeutische Zubereitung mit Gemfibrozil als aktiver Inhaltsstoff und Verfahren zur Herstellung
WO2002055062A3 (fr) Comprime pharmaceutique comprenant du mesylate de paroxetine
DK0911038T3 (da) Vandfri sammensætning omfattende lactulose
NZ509593A (en) Compressed compositions comprising clarified xanthan gum
KR970061250A (ko) 글리클라자이드-함유 연질캅셀제 내용물의 조성물
ES2133052A1 (es) Nuevas formulaciones farmaceuticas liquidas para la via oral.

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
HC1A Change of owner name